Addition of Denosumab to Neoadjuvant Chemo Does Not Lead to Significant iDFS Differences in Early Breast Cancer
The addition of denosumab (Prolia) to neoadjuvant nab-paclitaxel (Abraxane) did not lead to a statistically significant difference in invasive disease-free survival (iDFS) compared with nab-paclitaxel alone in patients with early-stage breast cancer, …